UY35460A - Formulaciones de anticuerpos anti-receptor de prolactina - Google Patents

Formulaciones de anticuerpos anti-receptor de prolactina

Info

Publication number
UY35460A
UY35460A UY0001035460A UY35460A UY35460A UY 35460 A UY35460 A UY 35460A UY 0001035460 A UY0001035460 A UY 0001035460A UY 35460 A UY35460 A UY 35460A UY 35460 A UY35460 A UY 35460A
Authority
UY
Uruguay
Prior art keywords
prolactin
formulations
receiver
antibodies anti
antibodies
Prior art date
Application number
UY0001035460A
Other languages
English (en)
Spanish (es)
Inventor
Ma Xinghang
Niu Jianjie
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of UY35460A publication Critical patent/UY35460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
UY0001035460A 2013-03-15 2014-03-14 Formulaciones de anticuerpos anti-receptor de prolactina UY35460A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361799629P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY35460A true UY35460A (es) 2014-10-31

Family

ID=50678293

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035460A UY35460A (es) 2013-03-15 2014-03-14 Formulaciones de anticuerpos anti-receptor de prolactina

Country Status (10)

Country Link
US (2) US9023357B2 (OSRAM)
EP (1) EP2968538A1 (OSRAM)
JP (1) JP2016515515A (OSRAM)
CN (1) CN105025925A (OSRAM)
AR (1) AR095496A1 (OSRAM)
CA (1) CA2906101A1 (OSRAM)
HK (1) HK1215175A1 (OSRAM)
TW (1) TW201513882A (OSRAM)
UY (1) UY35460A (OSRAM)
WO (1) WO2014143909A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036225B1 (ru) 2012-03-14 2020-10-15 Ридженерон Фармасьютикалз, Инк. Мультиспецифические антигенсвязывающие молекулы и их применения
CN105025925A (zh) * 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
JP6897570B2 (ja) 2015-12-18 2021-06-30 アステラス製薬株式会社 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
IL249795B (en) * 2016-02-05 2020-01-30 Grifols Worldwide Operations Ltd Intradermal administration of an immunoglobulin preparation g
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EP3518971A4 (en) 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
MX2019006131A (es) 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.
NZ757965A (en) * 2017-03-16 2022-07-01 Lg Chemical Ltd Liquid formulation of anti-tnf alpha antibody
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
TWI842672B (zh) 2017-04-13 2024-05-21 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法
HRP20221448T1 (hr) * 2018-01-26 2023-01-20 F. Hoffmann - La Roche Ag Il-22 fc pripravci i postupci njihove primjene
AU2019218892B2 (en) 2018-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
WO2024102675A1 (en) 2022-11-07 2024-05-16 Upstream Bio, Inc. Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2004055164A2 (en) * 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2423231A3 (en) * 2006-08-18 2012-05-30 Novartis AG PRLR-specific antibody and uses thereof
US8323653B2 (en) * 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
TW200831133A (en) * 2006-12-11 2008-08-01 Hoffmann La Roche Mab Abeta lyophylized formulation
EP2109460B1 (en) 2007-01-11 2016-05-18 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
JP5524967B2 (ja) * 2008-09-19 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 新規抗体処方物
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011080209A2 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN105025925A (zh) * 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂

Also Published As

Publication number Publication date
EP2968538A1 (en) 2016-01-20
US20160002342A1 (en) 2016-01-07
TW201513882A (zh) 2015-04-16
HK1215175A1 (zh) 2016-08-19
US9023357B2 (en) 2015-05-05
CN105025925A (zh) 2015-11-04
JP2016515515A (ja) 2016-05-30
AR095496A1 (es) 2015-10-21
CA2906101A1 (en) 2014-09-18
US20140271659A1 (en) 2014-09-18
WO2014143909A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
UY35460A (es) Formulaciones de anticuerpos anti-receptor de prolactina
CL2020000281A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39
UY34999A (es) Formulaciones de anticuerpos anti-receptor de prolactina
MX2022014781A (es) Formulaciones de anticuerpos anti-pdl1.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201792613A1 (ru) Модуляторы cot и способы их применения
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
EA201592213A1 (ru) Антитела антирецептор трансферрина и способы их использования
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX2020001752A (es) Anticuerpos anti-cd3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
BR112015028171A8 (pt) Inibidores de acc e seu uso
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
BR112015032224A2 (pt) anticorpos anti-fcrh5
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
TWD182434S (zh) 修枝剪刀(一)
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
MX2019001026A (es) Anticuerpos de antihemaglutinina y metodos de uso.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
EA201591962A1 (ru) Ингибиторы акк и их применение

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206